NANOSTRING TECHNOLOGIES INC. (Bruker Spatial Biology Inc.)

Company Snapshot

Founded: 2003
Entity Type: Public
Employees: 703
Region: Americas
Revenue: $127.3 Millions
Revenue Year: 2022
Headquarter: Washington, U.S.
Key Geographics: Americas, Europe and Middle East, Asia Pacific
Corporate Address: 530 Fairview Avenue North Seattle, Washington 98109 U.S. Tel. +1-206-378-6266 www.nanostring.com

Company Overview

NanoString Technologies Inc. is developing and marketing technologies for targeted detection of biological markers. NanoString’s platform technology is nCounter, which is very sensitive and detects a wide range of markers including DNA, RNA and proteins. nCounter is able to count a single biomarker and can detect up to 800 unique biomarkers from the same sample. The nCounter instrument uses proprietary consumables and is automated.

Newer technology platforms that the company is developing include hybridization-based sequencing (Hyb & Seq) and Digital Spatial Profiling (DSP).

The Hyb & Seq platform has been shown to be useful for liquid biopsy downstream analysis of cfDNA. For this application, the advantage of Hyb & Seq is that it can directly capture and analyze cfDNA without amplification or library construction. This gives a high yield of cfDNA with minimal contamination from cellular genomic DNA.

In December 2019, NanoString licensed its nCounter platform to Veracyte for diagnostic use. This deal enables NanoString to focus on being a research platform provider, including its nCounter gene expression profiling instruments and increasing adoption of its GeoMx Digital Spatial Profiler platform. Growing the customer base for the GeoMx platform is the company’s highest priority.

In October 2023, ASTAR’s Genome Institute of Singapore (GIS), NanoString Technologies Inc. and Next Level Genomics (NLG) announced the creation of the SpACE-Dx lab in Singapore. This joint laboratory, situated at ASTAR’s GIS facility, will specialize in applying spatial biology to identify biomarkers for predicting disease progression and treatment response, particularly in cancer. The lab will leverage spatial multiomic technologies to advance research in complex diseases, promoting collaboration and accelerating spatial genomics advancements within the local research community.

NANOSTRING TECHNOLOGIES INC. (Bruker Spatial Biology Inc.) In Reports

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

Discover BCC Research's report on Next-generation Sequencing Market is steadily being integrated into clinical laboratory analysis, testing, and disease diagnostics in healthcare sectors globally.

MicroRNA Research Tools, Diagnostics and Therapeutics: Global Markets

BCC Research Market Report says global artificial organs market should reach $17.7 billion by 2028 from $14.4 billion in 2023 at a compound annual growth rate of 4.2%.

Global Spatial Genomics and Transcriptomics Market

BCC Research Market Analysis Report for Spatial Genomics & Transcriptomics is estimated to increase from $1.5 bln in 2022 to reach $2.5 bln by 2027 at CAGR of 10.8%.

Company's Business Segments

  • Product : This segment inclues Instruments, Consumables.
  • Service : We Develop, Deliver, Manage Cloud-based Services.

Applications/End User Industries

  • Genomics
  • Proteomics
  • Clinical Research
  • Pharmaceuticals
  • Healthcare
  • Immunology
  • Neurology
  • Genes
  • Biopharmaceutical
  • Laboratories
  • Spatial Biology Platforms
  • Human Genomes
  • Mutations
  • Human Clinical Trials
  • Life Science Researchers
AI: Your Say